StockNews.AI
EMBC
StockNews.AI
52 days

embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results

1. Embecta will discuss Q4 and FY2024 results on Nov 26, 2024. 2. Preliminary guidance for FY2025 will be provided during the call. 3. The company emphasized its century-long legacy in insulin delivery.

3 mins saved
Full Article

FAQ

Why Bullish?

Positive future guidance can boost investor confidence, similar to past earnings calls.

How important is it?

Earnings updates and guidance are critical for investor sentiment and stock performance.

Why Short Term?

Immediate impact expected from upcoming financial results and guidance.

Related Companies

DBVTMDTTNDM
November 12, 2024 17:00 ET | Source: Embecta Corp. PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal fourth quarter and full year 2024 financial results, and provide an operational update, including preliminary fiscal year 2025 financial guidance, at 8:00 a.m. Eastern Time (ET) on Thursday, November 26, 2024. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.embecta.com. A webcast replay of the call will be available beginning at 11:00 a.m. ET on Nov 21, 2024, via the embecta investor relations website and archived on the website for one year. About embecta embecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, and Instagram. Contacts:   Media     Investors  Christian Glazar Pravesh KhandelwalSr. Director, Corporate Communications      VP, Head of Investor Relations908-821-6922   551-264-6547 Contact Media RelationsContact IR

Related News